Collagenase Clostridium Histolyticum: A Review in Peyronie’s Disease
- 72 Downloads
Collagenase Clostridium Histolyticum (hereafter referred to as CCH) [Xiaflex®; Xiapex®] is a mixture of two Clostridium histolyticum collagenases [AUX-I (a Class I clostridial collagenase) and AUX-II (a Class II clostridial collagenase)]. Administered by intralesional injection, it is available in various countries for the treatment of adult men with Peyronie’s disease (PD). In two double-blind, multinational, phase III studies, CCH improved the physical (penile curvature) and psychological (patient-reported bother) aspects of PD in adult men. Such beneficial effects were also seen in two open-label, multinational, phase III studies, with potential benefits for patients’ partners and maintained efficacy over up to 5 years additionally reported. Moreover, large real-world studies generally supported the therapeutic efficacy of CCH. CCH was generally well tolerated in these patient populations, with most treatment-related adverse events [TRAEs; most commonly penile haematoma (or ‘bruising’), pain and swelling] being mild or moderate in severity, not serious and resolving without intervention. Moreover, the use of CCH was not associated with penile length shortening. Current evidence indicates that CCH is an effective, generally well tolerated and, compared with surgery, minimally invasive option for the treatment of adult men with PD.
During the peer review process, the manufacturer of Collagenase Clostridium Histolyticum was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Sheridan Hoy is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
- 1.American Urological Association. Peyronie’s disease: AUA guideline; 2015. http://www.auanet.org/guidelines/peyronies-disease-guideline. Accessed 26 July 2019.
- 3.European Medicines Agency. Xiapex (collagenase clostridium histolyticum): EU assessment report; 2014. http://www.ema.europa.eu/. Accessed 15 July 2019.
- 6.Hatzimouratidis K, Giuliano F, Moncada I, et al. EAU guidelines on penile curvature; 2017. http://uroweb.org/guideline/penile-curvature/. Accessed 26 July 2019.
- 7.Paulis G. Natural history of Peyronie’s disease. In: Cavallini G, Paulis G, editors. Peyronie’s disease: a comprehensive guide. Cham: Springer; 2015. p. 27–37.Google Scholar
- 9.Swedish Orphan Biovitrum AB. Xiapex (collagenase clostridium histolyticum) 0.9 mg powder and solvent for solution for injection: EU summary of product characteristics; 2017. http://www.ema.europa.eu/. Accessed 6 June 2019.
- 10.Endo Pharmaceuticals Inc. XIAFLEX® (collagenase clostridium histolyticum) for injection, for intralesional use: US prescribing information; 2016. http://www.fda.gov/. Accessed 6 June 2019.
- 11.Endo Ventures Ltd. XIAFLEX® (collagenase clostridium histolyticum) lyophilized powder for solution 0.9 mg/vial: Canadian product monograph; 2019. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. Accessed 30 July 2019.
- 15.Data on file, Endo Pharmaceuticals Inc.; 2013.Google Scholar
- 26.Goldstein I, Liu G, McLane M, et al. Impact of collagenase clostridium histolyticum treatment of men with Peyronie’s disease on improvement of female partner sexual function [abstract no. PD54-05]. J Urol. 2018;199(4 Suppl):e1053.Google Scholar
- 33.Sun A, Li S, Eisenberg M. Corporal rupture and collagenase clostridium histolyticum: a population based study [abstract no. PD44-05]. J Urol. 2018;199(4 Suppl):e882–3.Google Scholar